Global Market: Sweden

Sweden has one of the most well-developed healthcare system in the world. A market that is increasingly being shaped by digital transformation driven by both innovation and structural demand.

Population (24’): 10.5million GDP per Capital(24): $57,117

Life Expectancy (23’): 83 yrs Currency: Swedish Krona

MedTech Maturity level: highly mature

Population Dynamics: Aging populationdriven by high life expectancy and low mortality rates

Health System Structure

• Governance model: Sweden has a nationally regulated and locally administered universal health system. Health and medical care priorities are guided by three basic principles;

  • Human dignity: That all human beings have an equal entitlement to dignity and have the same rights regardless of their status in the community

  • Need and solidarity: That those in greatest need take precedence in being treated

  • Cost-effectiveness: When a choice for medical care has to be made, there should be a reasonable balance between cost and benefits, with cost measured in relation to improvement in health and quality of life
    
    

• Coverage model: Healthcare coverage is universal and automatic. Private health insurance is available and accounts for less than 1% of expenditures and used as supplementary. There are no defined benefit package for the publicly financed plans
  
  

• Role of government: Responsibilities for healthcare is shared between the state, 21 regional authorities and the 290 municipalities

  • The state, through the Ministry of Health and Social Affairs, is responsible for the overall health and health care policy

  • The regional authorities are responsible for financing and delivering health services to their citizens

  • At the local level, 290 municipalities are responsible for matters relating to the environment of their citizens
    
    

  Procurement pathways: Sweden procurement process is fully decentralized with purchasing decisions made at regional and municipal levels. The 21 regions and 290 municipalities each managing their own procurement.
  
  

Health authorities under the ministry of social affairs (English names);

• The National Board of Health and Welfare (NBHW), acts as the central authority for social services, health services, and related sector

• The Dental and Pharmaceutical Benefit Agency (TLV), responsible for determining which prescription medicines, medical devices, and dental care procedures are subsidized by the state

• The Agency for Health Technology Assessment and Assessment of Social Services (SBU), responsible for independently assessing medical products and medical interventions by summarizing and communicating related evidence

• The Medical Products Agency (MPA), responsible for regulation and surveillance of the development, manufacturing and sale of drugs and other medicinal products

• The Agency for Health and Care Services Analysis, whose main responsibility is to evaluate and review the effectiveness of healthcare and social services from a person-centered perspective

• The e-Health Agency, works to digitalize and improve the sharing of information between patients, the healthcare system and pharmacies

Reimbursement Environment

• Reimbursement mechanisms: Hospitals are reimbursed through annual global budgets or a mix of global budgets, diagnosis‑related groups (DRG), and performance‑based payment models. Outpatient specialist care is funded either through fee‑for‑service or bundled payments, in which providers receive a single payment for the full care episode regardless of the number of patient contacts. Primary care is reimbursed primarily through fixed capitation, paid per patient registered with the primary care center, independent of whether the patient seeks care.

• HTA maturity: Mature and well established, its main responsibility is to inform healthcare policy, reimbursement and clinical practice. The HTA networks in Sweden, consists of representatives from government agencies, regional and local health technology assessment units, as well as other organizations working in medical evaluation. Its purpose is to coordinate efforts across the system, reduce duplication, promote methodological alignment, support education, and advance the development of HTA practices in Sweden.

• Pricing controls: Prices are governed through annual global budgets or a combination of global budgets and performance‑based payment models. County councils and municipalities are legally required to establish these budgets and ensure that their healthcare activities remain financially balanced. Medical device reimbursement is included in hospital funding.

• Time to reimbursement: There is no published standardized timeline to reimbursement for medical devices in Sweden.

• Coding classification: Sweden uses the NordDRG case‑mix classification system as the foundation for DRG‑based reimbursement, although individual regions adapt the system within their own budgeting and payment frameworks

Value Drivers for Medical Technology

• Clinical and Economic evidence expectations: Sweden’s HTA processes prioritize robust comparative clinical evidence within the indicated population, supported by cost‑effectiveness or cost‑minimization analyses to determine the product’s value

• Innovation appetite: high, especially for digital health and artificial intelligence

• Digital readiness: ready and growing fast, driven by investments and a focus on integrated care.

Population & Demographic Baseline

• Population size(24’): 10.5 million

• Age distribution(23’): 22.9% aged 65+

• Disease burden: 34-37% of the population has at least 1 chronic disease

• Healthcare spending per capital(24’): $6,484

• Healthcare workforce density(20’):

  • Physicians per 1,000: 4.1

  • Nurses per 1,000: 10.9

  • Hospital beds per 1,000: 2.2

Economic Standing

Past

• GDP growth patterns: GDP has fluctuated with modest growth.

• Healthcare spending as % of GDP: Spending has increased from 8.32 in 2010, to 10.93 in 2019 and 11.2 in 2024.

• Import vs local production trends: Sweden has a robust export Medtech sector but remains reliant on imports from key suppliers in US, Germany and Netherlands

Present

• Current GDP and stability (25’): stable, projected to be 620.3 billion with expected increase from 1.5% in 2025 to 2.6% in 2026

• Healthcare budget priorities: Sweden has a focus on strengthening local care systems driven by expanding elderly care and rise of chronic disease. The government has increased focus on preventative care and a desire to remain a leader in technology innovation.

• MedTech market size: Sweden imports approximately 73% of its medical device, continues to be import dependent country

Future

• Demographic pressure scenarios: An aging population is driving a rise in chronic disease increasing the need for advanced medical technology

• Expected Policy changes: Sweden will align its future policies with broader European Union initiatives, along placing greater emphasis on digital health and artificial intelligence

• Digital transformation outlook: continued demand for digital solutions that are technically advanced and ready to integrate seamlessly into the healthcare system.

Regional Opportunity & Risk Summary

• Market attractiveness drivers: Sweden’s MedTech landscape is highly receptive to innovation, supported by an aging population that is steadily increasing demand for advanced medical technologies.

• Key barriers to product entry: The Swedish market offers multiple access points, successful and strong local partnerships can ease entry. Public procurement places significant emphasis on value, system integration,and sustainability. Products must be CE-marked, accompanies by documentation in Swedish, compliant with GDPR, and competitively priced.

Strategic Market Entry Recommendations

• Those entering the Swedish market should establish early and strong local partnerships. A credible Swedish presence unlocks influence networks, accelerates clinician adoption, and smooths navigation through the country’s highly decentralized procurement landscape.

• Sweden has a rising demand for AI-powered technologies and digital health solutions that integrate smoothly with existing systems. It’s important to validate your digital solution against the Swedish healthcare system before entry to increase likelihood of successful adoption

In conclusion,Sweden presents a compelling market for digital health and artificial intelligence, but success will depend on strong integration, preparation, strategic partnerships, and full regulatory readiness.